210 related articles for article (PubMed ID: 37607536)
1. A pan-cancer single-cell panorama of human natural killer cells.
Tang F; Li J; Qi L; Liu D; Bo Y; Qin S; Miao Y; Yu K; Hou W; Li J; Peng J; Tian Z; Zhu L; Peng H; Wang D; Zhang Z
Cell; 2023 Sep; 186(19):4235-4251.e20. PubMed ID: 37607536
[TBL] [Abstract][Full Text] [Related]
2. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
3. Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression.
Bruno A; Mortara L; Baci D; Noonan DM; Albini A
Front Immunol; 2019; 10():771. PubMed ID: 31057536
[TBL] [Abstract][Full Text] [Related]
4. Bidirectional interactions of NK cells and dendritic cells in immunotherapy: current and future perspective.
Mahmood S; Upreti D; Sow I; Amari A; Nandagopal S; Kung SK
Immunotherapy; 2015; 7(3):301-8. PubMed ID: 25804481
[TBL] [Abstract][Full Text] [Related]
5. The Natural Killer-Dendritic Cell Immune Axis in Anti-Cancer Immunity and Immunotherapy.
Peterson EE; Barry KC
Front Immunol; 2020; 11():621254. PubMed ID: 33613552
[TBL] [Abstract][Full Text] [Related]
6. NK Cells in the Tumor Microenvironment.
Guillerey C
Adv Exp Med Biol; 2020; 1273():69-90. PubMed ID: 33119876
[TBL] [Abstract][Full Text] [Related]
7. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cells and solid tumors.
Stojanovic A; Cerwenka A
J Innate Immun; 2011; 3(4):355-64. PubMed ID: 21502747
[TBL] [Abstract][Full Text] [Related]
9. NK Cell Anti-Tumor Surveillance in a Myeloid Cell-Shaped Environment.
Russo E; Laffranchi M; Tomaipitinca L; Del Prete A; Santoni A; Sozzani S; Bernardini G
Front Immunol; 2021; 12():787116. PubMed ID: 34975880
[TBL] [Abstract][Full Text] [Related]
10. The Adverse Impact of Tumor Microenvironment on NK-Cell.
Hu Z; Xu X; Wei H
Front Immunol; 2021; 12():633361. PubMed ID: 34177887
[TBL] [Abstract][Full Text] [Related]
11. Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer.
Bödder J; Zahan T; van Slooten R; Schreibelt G; de Vries IJM; Flórez-Grau G
Front Immunol; 2020; 11():631713. PubMed ID: 33679726
[TBL] [Abstract][Full Text] [Related]
12. Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1α Unleashes NK Cell Activity.
Ni J; Wang X; Stojanovic A; Zhang Q; Wincher M; Bühler L; Arnold A; Correia MP; Winkler M; Koch PS; Sexl V; Höfer T; Cerwenka A
Immunity; 2020 Jun; 52(6):1075-1087.e8. PubMed ID: 32445619
[TBL] [Abstract][Full Text] [Related]
13. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.
Barry KC; Hsu J; Broz ML; Cueto FJ; Binnewies M; Combes AJ; Nelson AE; Loo K; Kumar R; Rosenblum MD; Alvarado MD; Wolf DM; Bogunovic D; Bhardwaj N; Daud AI; Ha PK; Ryan WR; Pollack JL; Samad B; Asthana S; Chan V; Krummel MF
Nat Med; 2018 Aug; 24(8):1178-1191. PubMed ID: 29942093
[TBL] [Abstract][Full Text] [Related]
14. Human NK cells: From surface receptors to clinical applications.
Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
[TBL] [Abstract][Full Text] [Related]
15. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.
Deauvieau F; Ollion V; Doffin AC; Achard C; Fonteneau JF; Verronese E; Durand I; Ghittoni R; Marvel J; Dezutter-Dambuyant C; Walzer T; Vie H; Perrot I; Goutagny N; Caux C; Valladeau-Guilemond J
Int J Cancer; 2015 Mar; 136(5):1085-94. PubMed ID: 25046660
[TBL] [Abstract][Full Text] [Related]
16. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
[TBL] [Abstract][Full Text] [Related]
17. The interaction of NK cells and dendritic cells in the tumor environment: how to enforce NK cell & DC action under immunosuppressive conditions?
Jacobs B; Ullrich E
Curr Med Chem; 2012; 19(12):1771-9. PubMed ID: 22414086
[TBL] [Abstract][Full Text] [Related]
18. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
[TBL] [Abstract][Full Text] [Related]
19. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
Ghaedrahmati F; Esmaeil N; Abbaspour M
Cancer Commun (Lond); 2023 Feb; 43(2):177-213. PubMed ID: 36585761
[TBL] [Abstract][Full Text] [Related]
20. NK cell-based cancer immunotherapy: from basic biology to clinical application.
Li Y; Yin J; Li T; Huang S; Yan H; Leavenworth J; Wang X
Sci China Life Sci; 2015 Dec; 58(12):1233-45. PubMed ID: 26588912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
